Phase 2 · NCT04881760
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
What this means
The registry describes the study design and status. This label does not mean results have been reported.
Figure / record sourceLast verified 23 Oct 2026
Registry record
Trial details
- Trial
- A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
- ClinicalTrials.gov ID
- NCT04881760
- Indication
- Obesity, Overweight
- Phase
- Phase 2
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 338
- Status
- Completed
- Interventions
- Drug: LY3437943; Drug: Placebo
- Comparator
- Placebo
- Eligible ages
- 18 Years – 75 Years
- Locations
- 28 sites · Puerto Rico, United States
- Study start
- 20 May 2021
- Primary completion
- 16 May 2022
- Study completion
- 22 Nov 2022
Verification
- Last verified
- 23 Oct 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 13 Sept 2023
Endpoints
Primary
Mean Percent Change From Baseline in Body Weight
Secondary
Mean Percent Change From Baseline in Body Weight; Percentage of Participants Who Achieve ≥ 5% Body Weight Reduction; Percentage of Participants Who Achieve ≥ 5% Body Weight Reduction; Percentage of Participants Who Achieve ≥ 10% Body Weight Reduction; Percentage of Participants Who Achieve ≥ 10% Body Weight Reduction; Percentage of Participants Who Achieve ≥ 15% Body Weight Reduction; Percentage of Participants Who Achieve ≥ 15% Body Weight Reduction; Mean Change From Baseline in Body Weight; Mean Change From Baseline in Body Weight; Mean Change From Baseline in BMI; Mean Change From Baseline in BMI; Mean Change From Baseline in Waist Circumference; Mean Change From Baseline in Waist Circumference